Improving the treatment of schizophrenia: Role of 5-HT receptors in modulating cognitive and extrapyramidal motor functions

CNS and Neurological Disorders - Drug Targets

Volumn 12, Issue 6, 2013, Pages 861-869

  Shimizu, Saki ^a   Mizuguchi, Yuto ^a   Ohno, Yukihiro ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

5 HT receptors; Antipsychotics; Cognitive impairments; Extrapyramidal side effects; Schizophrenia

Indexed keywords

ADENYLATE CYCLASE; ARIPIPRAZOLE; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE; CLOZAPINE; CYCLIC AMP DEPENDENT PROTEIN KINASE; DIACYLGLYCEROL; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; G PROTEIN COUPLED INWARDLY RECTIFYING POTASSIUM CHANNEL; INOSITOL TRISPHOSPHATE; LURASIDONE; OLANZAPINE; PHOSPHOLIPASE C; PROTEIN KINASE C; QUETIAPINE; RISPERIDONE; SEROTONIN 1A ANTAGONIST; SEROTONIN 1A RECEPTOR; SEROTONIN 2A ANTAGONIST; SEROTONIN 2A RECEPTOR; SEROTONIN 2C ANTAGONIST; SEROTONIN 2C RECEPTOR; SEROTONIN 3 ANTAGONIST; SEROTONIN 3 RECEPTOR; SEROTONIN 4 AGONIST; SEROTONIN 4 RECEPTOR; SEROTONIN 6 ANTAGONIST; SEROTONIN 6 RECEPTOR; SEROTONIN RECEPTOR; UNINDEXED DRUG;

ANXIETY; BRAIN CORTEX; COGNITION; COGNITIVE DEFECT; DEPOLARIZATION; DEPRESSION; EXTRAPYRAMIDAL SYNDROME; EXTRAPYRAMIDAL SYSTEM; HIPPOCAMPUS; HUMAN; HYPERPOLARIZATION; LEARNING DISORDER; MEMORY DISORDER; NONHUMAN; POSITIVE AND NEGATIVE SYNDROME SCALE; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION;

ANIMALS; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; COGNITION DISORDERS; HUMANS; RECEPTORS, SEROTONIN; SCHIZOPHRENIA; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 84880961736     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/18715273113129990088     Document Type: Review

References (100)

1. Meltzer, H.Y. The Mechanism of Action of Novel Antipsychotic Drugs. Schizophr. Bull., 1991, 17(2), 263-287.
2. Kapur, S.; Remington, G. Atypical antipsychotics:new directions and new challenges in the treatment of schizophrenia. Ann. Rev. Med., 2001, 52, 503-517.
3. 1A receptors in central nervous system disorders. Cent. Nerv. Syst. Agents Med. Chem., 2010, 10(2), 148-157.
4. 1A receptors in the treatment of schizophrenia and Parkinson's disease. CNS Neurosci. Ther., 2011, 17(1), 58-65.
5. Meltzer, H.Y.; Stahl, S.M. The dopamine hypothesis of schizophrenia: a review. Schizophr. Bull., 1976, 2(1), 19-76.
6. Seeman, P. Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse, 1987, 1(2), 133-152.
7. 2 receptor interaction in the atypical antipsychotic action of the novel succimide derivative, perospirone. Pol. J. Pharmacol., 1997, 49(4), 213-219.
8. Meltzer, H.Y.; Li, Z.; Kaneda, Y.; Ichikawa, J. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiat., 2003, 27(7), 1159-1172.
9. Bleich, A.; Brown, S.L.; Kahn, R.; van Praag, H.M. The role of serotonin in schizophrenia. Schizophr. Bull., 1988, 14(2), 297-315.
10. Breier, A. Serotonin, schizophrenia and antipsychotic drug action. Schizophr. Res., 1995, 14(3), 187-202.
11. 2 receptor partial agonist. Expert Opin. Investig. Drugs, 2007, 16(6), 771-775.
12. Lieberman, J.A.; Stroup, T.S.; McEvoy, J. P.; Swartz, M.S.; Rosenheck, R.A.; Perkins, D.O.; Keefe, R.S.; Davis, S.M.; Davis, C.E.; Lebowitz, B.D.; Severe, J.; Hsiao, J.K. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med., 2005, 353(12), 1209-1223.
13. Keefe, R.S.; Bilder, R.M.; Davis, S.M.; Harvey, P.D.; Palmer, B.W.; Gold, J.M.; Meltzer, H.Y.; Green, M.F.; Capuano, G.; Stroup, T.S.; McEvoy, J.P.; Swartz, M.S.; Rosenheck, R.A.; Perkins, D.O.; Davis, C.E.; Hsiao, J.; Lieberman, J.A. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch. Gen. Psychiatry, 2007, 64(6), 633-647.
14. Davidson, M.; Galderisi, S.; Weiser, M.; Werbeloff, N.; Fleischhacker, W.W.; Keefe, R.S.; Boter, H.; Keet, I.P.; Prelipceanu, D.; Rybakowski, J.K.; Libiger, J.; Hummer, M.; Dollfus, S.; López-Ibor, J.J.; Hranov, L.G.; Gaebel, W.; Peuskens, J.; Lindefors, N.; Riecher-Rössler, A.; Kahn, R.S. Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). Am. J. Psychiatry, 2009, 166(6), 675-682.
15. Roth, B.L. Multiple serotonin receptors: clinical and experimental aspects. Ann. Clin. Psychiatry, 1994, 6(2), 67-78.
16. Barnes, N.M.; Sharp, T. A review of central 5-HT receptors and their function. Neuropharmacology, 1999, 38(8), 1083-1152.
17. 6 receptors in learning and memory. Trends Pharmacol. Sci., 2008, 29(9), 482-492.
18. 3 receptors: role in disease and target of drugs. Pharmacol. Ther., 2010, 128(1), 146-169.
19. 1A Receptors. Aging Dis., 2013, 4(1), 1-13.
20. Pucadyil, T.J.; Kalipatnapu, S.; Chattopadhyay, A. The serotonin1A receptor: a representative member of the serotonin receptor family. Cell Mol. Neurobiol., 2005, 25(3-4), 553-580.
21. 1A receptor ligands on rat dorso-lateral septal neurones in vitro. Br. J. Pharmacol., 1992, 106(4), 893-899.
22. Hadrava, V.; Blier, P.; Dennis, T.; Ortemann, C.; de Montigny, C. Characterization of 5-hydroxytryptamine1A properties of flesinoxan: in vivo electrophysiology and hypothermia study. Neuropharmacology, 1995, 34(10), 1311-1326.
23. 1A agonist, on activities of the lateral septal nucleus neurons in cats. In: Takada, Y., Curzon, G., Eds.; Serotonin in the central nervous system and periphery. Elsevier Science BV. Amsterdam, 1995, pp. 159-165.
24. 1A receptor: G protein coupling and signalling pathways. Br. J. Pharmacol., 1999, 127(8), 1751-1764.
25. Tada, K.; Kasamo, K.; Ueda, N.; Suzuki, T.; Kojima, T.; Ishikawa, K. Anxiolytic 5-Hydroxytryptamine1A Agonists Suppress Firing Activity of Dorsal Hippocampus CA1 Pyramidal Neurons through a Postsynaptic Mechanism: Single-Unit Study in Unanesthetized, Unrestrained Rats. J. Pharmacol. Exp. Ther., 1999, 288(2), 843-848.
26. Feighner, J.P.; Boyer, W. F. Serotonin-1A Anxiolytics: An Overview. Psychopathol. Suppl., 1989, 22, 21-26.
27. Fuller, R.W. Role of serotonin in therapy of depression and related disorders. J. Clin. Psychiatry Suppl., 1991, 52, 52-57.
28. Ohno, Y. Tandospirone citrate, a new serotonergic anxiolytic agent: A potential use in Parkinson's disease. In: Mizuno, Y.; Fisher, A.; Hanin, I., Eds.; Mapping the Progress of Alzheimer's and Parkinson's Disease. Kluwer Academic/Plenum, New York, 2002, pp. 423-428.
29. Kusserow, H.; Davies, B.; Hörtnagl, H.; Voigt, I.; Stroh, T.; Bert, B.; Deng, D.R.; Fink, H.; Veh, R.W.; Theuring, F. Reduced anxiety-related behaviour in transgenic mice overexpressing serotonin1A receptors. Mol. Brain Res., 2004, 129(1-2), 104-116.
30. Akimova, E.; Lanzenberger, R.; Kasper, S. The Serotonin-1A Receptor in Anxiety Disorders. Biol. Psychiatry, 2009, 66(7), 627-635.
31. 2+ Permeability and Conduction in the Human 5-Hydroxytryptamine Type 3A Receptor. J. Biol. Chem., 2008, 283(28), 19301-19313.
32. 6 with neuropeptides in rat striatum. J. Comp. Neurol., 1996, 370(3), 405-414.
33. 6 Receptors. CNS Neurol. Disord. Drug Targets, 2004, 3(1), 59-79.
34. 6 receptormediated acetylcholine release. Eur. J. Neurosci., 2006, 24(5), 1299-1306.
35. 7 recepter research. Trends Pharmacol. Sci., 2004, 25(9), 481-486.
36. 1A antagonists WAY 100635 and NAD-299 attenuate the impairment of passive avoidance caused by scopolamine in the rat. Neuropsychopharmacology, 2003, 28(2), 253-264.
37. 1A receptors in spatial and aversive learning in the rat. Neuropharmacology, 2005, 48(6), 830-852.
38. Madjid, N.; Tottie, E.E.; Lüttgen, M.; Meister, B.; Sandin, J.; Kuzmin, A.; Stiedl, O.; Ogren, S.O. 5-Hydroxytryptamine 1A receptor blockade facilitates aversive learning in mice: interactions with cholinergic and glutamatergic mechanisms. J. Pharmacol. Exp. Ther., 2006, 316(2), 581-591.
39. 1A receptors in learning and memory. Behav. Brain Res., 2008, 195(1), 54-77.
40. 3 receptor antagonist, on cognition in rodents and primates. Pharmacol. Biochem. Behav., 1990, 35(4), 955-962.
41. 3 receptor antagonists WAY-100579 and ondansetron on spatial learning in the water maze in rats with excitotoxic lesions of the forebrain cholinergic projection system. Psychopharmacology (Berl.), 1996, 125(2), 146-161.
42. 3 receptor antagonists on cognitive performance in aged monkeys. Neurobiol. Aging, 1997, 18(1), 21-28.
43. Gil-Bea, F.J.; Domínguez, J.; García-Alloza, M.; Marcos, B.; Lasheras, B.; Ramirez, M.J. Facilitation of cholinergic transmission by combined treatment of ondansetron with flumazenil after cortical cholinergic deafferentation. Neuropharmacology, 2004, 47(2), 225-232.
44. Giovannini, M.G.; Ceccarelli, I.; Molinari, B.; Cecchi, M.; Goldfarb, J.; Blandina, P. Serotonergic modulation of acetylcholine release from cortex of freely moving rats. J. Pharmacol. Exp. Ther., 1998, 285(3), 1219-1225.
45. 4 receptor ligands in rat spatial navigation. Neuropharmacology, 1997, 36(4-5), 689-696.
46. 4 receptors in the mouse passive avoidance test. J. Pharmacol. Exp. Ther., 1998, 286(3), 1115-1121.
47. 4 receptors. Neuropharmacology, 2001, 41(7), 844-853.
48. 4 agonist, enhances memory and hippocampal acetylcholine efflux. Neuropharmacology, 2007, 53(4), 563-573.
49. 4 receptor stimulation facilitates acetylcholine release in rat frontal cortex. Neuroreport, 1994, 5(10), 1230-1232.
50. 4 receptor modulation of acetylcholine outflow in guinea pig brain slices. Neuroreport, 1999, 10(3), 547-551.
51. Bickmeyer, U.; Heine, M.; Manzke, T.; Richter, D.W. Differential modulation of I(h) by 5-HT receptors in mouse CA1 hippocampal neurons. Eur. J. Neurosci., 2002, 16(2), 209-218.
52. 6 receptors in the rat dorsomedial striatum impairs instrumental learning. Neuropsychopharmacology, 2007, 32(7), 1520-1530.
53. 6 receptors in retention of spatial learning in the Morris water maze. Neuropharmacology, 2001, 41(2), 210-219.
54. 6 receptor antagonist, Ro 04-6790. Psychopharmacology (Berl.), 2003, 170(4), 358-367.
55. 6 receptor antagonists reverse delay-dependent deficits in novel object discrimination by enhancing consolidation--an effect sensitive to NMDA receptor antagonism. Neuropharmacology, 2004, 47(2), 195-204.
56. 6 receptor antagonist Ro4368554 restores memory performance in cholinergic and serotonergic models of memory deficiency in the rat. Neuropsychopharmacology, 2005, 30(12), 2169-2179.
57. 6 receptor antagonist with cognitive enhancing properties in aged rat water maze and novel object recognition models. Eur. J. Pharmacol., 2006, 553(1-3), 109-119.
58. 6 Receptor Agonists: WAY-181187 and WAY-208466. Neuropsychopharmacology, 2008, 33(6), 1323-1335.
59. 6 receptor antagonist. J. Med. Chem., 2003, 46(7), 1273-1276.
60. 2A receptor antagonist M100,907 attenuates motor and 'impulsive-type' behaviours produced by NMDA receptor antagonism. Psychopharmacology (Berl.), 2003, 170(3), 309-319.
61. 2A receptors antagonist M100907 prevents impairment in attentional performance by NMDA receptor blockade in the rat prefrontal cortex. Neuropsychopharmacology, 2004, 29(9), 1637-1647.
62. 2C receptor antagonism is neuroanatomically specific. J. Neurosci., 2010, 30(3), 930-938.
63. Neal-Beliveau, B.S.; Joyce, J.N.; Lucki, I. Serotonergic involvement in haloperidol-induced catalepsy. J. Pharmacol. Exp. Ther., 1993, 265(1), 207-217.
64. Wadenberg, M.L.; Young, K.A.; Richter, J.T.; Hicks, P.B. Effects of local application of 5-hydroxytryptamine into the dorsal or median raphe nuclei on haloperidol-induced catalepsy in the rat. Neuropharmacology, 1999, 38(1), 151-156.
65. 1A receptor activation and anti-cataleptic effects: high-efficacy agonists maximally inhibit haloperidol-induced catalepsy. Eur. J. Pharmacol., 2002, 453(2-3), 217-221.
66. 1A agonist, tandospirone, in rats. Biog. Amines, 2004, 18(3-6), 329-338.
67. 1A agonists using the mouse pole test. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2008, 32(5), 1302-1307.
68. Ohno, Y.; Shimizu, S.; Imaki, J.; Ishihara, S.; Sofue, N.; Sasa M.; Kawai, Y. Anticataleptic 8-OH-DPAT preferentially counteracts with haloperidol-induced Fos expression in the dorsolateral striatum and the core region of the nucleus accumbens. Neuropharmacology, 2008, 55(5), 717-723.
69. 1A agonistic anxiolytic agent, on haloperidol-induced catalepsy and forebrain Fos expression in mice. J. Pharmacol. Sci., 2009, 109(4), 593-599.
70. 1A receptors mediate an increase in locomotor activity in the monoamine-depleted rat. Psychopharmacology, 2002, 163(1), 85-94.
71. 1A agonist with antipsychotic-and antiparkinsonian-like properties. Neuropharmacology, 2006, 51(1),129-140.
72. 1A receptors in alleviating antipsychotic-induced extrapyramidal disorders. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2010, 34(6), 877-881.
73. Chartoff, E.H.; Ward, R.P.; Dorsa, D.M. Role of adenosine and Nmethyl-D-aspartate receptors in mediating haloperidol-induced gene expression and catalepsy. J. Pharmacol. Exp. Ther., 1999, 291(2), 531-537.
74. Hussain, N.; Flumerfelt, B.A.; Rajakumar, N. Glutamatergic regulation of haloperidol-induced c-fos expression in the rat striatum and nucleus accumbens. Neuroscience, 2001, 102(2), 391-399.
75. 2 receptor antagonist, using the mouse pole test. Pharmacol. Biochem. Behav., 1994, 49(1), 19-23.
76. 6 receptors. Neuropharmacology, 2010, 60(2-3), 201-208.
77. Tatara, A.; Shimizu, S.; Shin, N.; Sato, M.; Sugiuchi, T.; Imaki, J.; Ohno, Y. Modulation of antipsychotic-induced extrapyramidal side effects by medications for mood disorders. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2012, 38(2), 252-259.
78. Ishibashi, T.; Ikeda, K.; Ishida, K.; Yasui, J.; Tojima, R.; Nakamura, M.; Ohno, Y. Contrasting effects of SM-9018, a potential atypical antipsychotic, and haloperidol on c-fos mRNA expression in the rat striatum. Eur. J. Pharmacol., 1996, 303(3), 247-251.
79. 2 receptor antagonist, on electrically-evoked [3H] acetylcholine release from rat striatal slices. Gen. Pharmacol., 1996, 27(7), 1203-1207.
80. Alex, K.D.; Pehek, E.A. Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission. Pharmacol. Ther., 2007, 113(2), 296-320.
81. 2 receptor effects of antipsychotics: bridging basic and clinical findings using PET. J. Clin. Psychiatry Suppl., 1999, 60, 15-19.
82. Horacek, J.; Bubenikova-Valesova, V.; Kopecek, M.; Palenicek, T.; Dockery, C.; Mohr, P.; Höschl, C. Mechanism of Action of Atypical Antipsychotic Drugs and the Neurobiology of Schizophrenia. CNS Drugs, 2006, 20(5), 389-409.
83. 2C receptor antagonist. Br. J. Pharmacol., 1999, 126(3), 572-574.
84. 2C receptor antagonists on acute and chronic dyskinetic effects induced by haloperidol in rats. Behav. Brain Res., 2011, 219(2), 273-279.
85. 3 receptor antagonists on neuroleptic-induced catalepsy in mice. Neuropharmacology, 1995, 34(1), 97-99.
86. 7 Serotonin Receptors: Implications for Extrapyramidal Side Effects of Serotonin Reuptake Inhibitors. Neuropsychopharmacology, 2007, 32(8), 1840-1854.
87. Schechter, L.E.; Smith, D.L.; Rosenzweig-Lipson, S.; Sukoff, S.J.; Dawson, L.A. Lecozotan (SRA-333): a selective serotonin 1A receptor antagonist that enhances the stimulated release of glutamate and acetylcholine in the hippocampus and possesses cognitive-enhancing properties. J. Pharmacol. Exp. Ther., 2005, 314(3), 1274-1289.
88. Sumiyoshi, T.; Matsui, M.; Nohara, S.; Yamashita, I.; Kurachi, M.; Sumiyoshi, C.; Jayathilake, K.; Meltzer, H.Y. Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment. Am. J. Psychiatry, 2001, 158(10), 1722-1725.
89. Sumiyoshi, T.; Park, S.; Jayathilake, K.; Roy, A.; Ertugrul, A., Meltzer, H.Y. Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: a randomized, double-blind, placebocontrolled study. Schizophr. Res., 2007, 95(1-3), 158-168.
90. 1A receptor properties. Psychopharmacology, 2011, 216, 451-473.
91. 1A receptor activity. J. Pharmacol. Exp. Ther., 2010, 334(1), 171-181.
92. Ishiyama, T.; Tokuda, K.; Ishibashi, T.; Ito, A.; Toma, S.; Ohno, Y. Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test. Eur. J. Pharmacol., 2007, 572(2-3), 160-170.
93. Enomoto, T.; Ishibashi, T.; Tokuda, K; Ishiyama, T; Toma, S; Ito, A. Lurasidone reverses MK-801-induced impairment of learning and memory in the Morris water maze and radial-arm maze tests in rats. Behav. Brain Res., 2008, 186(2), 197-207.
94. Zhang, Z.J.; Kang, W.H.; Li, Q.; Wang, X.Y.; Yao, S.M.; Ma, A.Q. Beneficial effects of ondansetron as an adjunct to haloperidol for chronic, treatment-resistant schizophrenia: a double-blind, randomized, placebo-controlled study. Schizophr. Res., 2006, 88(1-3), 102-110.
95. Akhondzadeh, S.; Mohammadi, N.; Noroozian, M.; Karamghadiri, N.; Ghoreishi, A.; Jamshidi, A.H.; Forghani, S. Added ondansetron for stable schizophrenia: a double blind, placebo controlled trial. Schizophr. Res., 2009, 107(2-3), 206-212.
96. Abbasi, S.H.; Behpournia, H.; Ghoreshi, A.; Salehi, B.; Raznahan, M.; Rezazadeh, S.A.; Rezaei, F.; Akhondzadeh, S. The effect of mirtazapine add on therapy to risperidone in the treatment of schizophrenia: A double-blind randomized placebo-controlled trial. Schizophr. Res., 2010, 116(2-3), 101-106.
97. Stenberg, J.H.; Terevnikov, V.; Joffe, M.; Tiihonen, J.; Tchoukhile, E.; Burkin, M.; Joffe, G. More evidence on proneurocognitive effects of add-on mirtazapine in schizophrenia., Prog. Neuro-Psychopharmacol. Biol. Psychiatry, 2011, 35(4):1080-1086.
98. 6 serotonin receptor. J. Neurochem., 1996, 66(1), 47-56.
99. 6 receptor in cognitive function., Neuropharmacology, 2008, 55, 1015-1022.
100. 6 receptorantagonists as novelcognitiveenhancingagents for Alzheimer's disease., Neurotherapeutics, 2008, 5(3), 458-469.